Brisbane, Australia, 29 December 2017 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the appointment of Mr Nathan Buzza as a Non-Executive Director, effective immediately. Mr Buzza is an experienced senior executive and director with 25 years’ experience in software, electronics and medical technology.
Mr Buzza was the founder of Commtech Wireless, a highly successful clinical middleware provider with offices in Australia, the United States, Europe and Asia. In 2008, Mr Buzza negotiated the trade sale of Commtech Wireless to Amcom Software and continued as General Manager for 18 months post acquisition. During Mr Buzza’s tenure, the business was listed by BRW as one of the fastest growing privately held companies in Australia for three consecutive years and the recipient of numerous accolades including the Telstra Small Business of the Year Award. In 2010, Amcom Software was acquired by Spok for US$163.8m. Mr Buzza was awarded the “Entrepreneur of the Year” from Ernst & Young in 2005 and received the Western Australian IT and Telecommunications Lifetime Achievement Award for his contribution to the IT community.
More recently, Mr Buzza was an Executive Director of Alcidion Group Limited (ASX:ALC), a provider of clinical decision support systems.
“I am privileged to be joining the board at such a pivotal moment in the Company’s history and help build upon the outstanding foundations that have already been laid,” said Mr Buzza.
The board has also accepted the resignation of Mr Brian Leedman who has served on the board since February 2016. Mr Leedman is a co-founder of the company and will continue in his role as Vice President, Corporate Affairs.
Dr Roger Aston, Chairman of ResApp commented, “Nathan’s appointment adds significant software and healthcare experience to the board and is demonstrative of the company’s transition to commercialisation in expectation of a successful SMARTCOUGH-C-2 clinical study. I’m pleased that Brian’s investor relations experience is being retained moving forward and would like to thank him on behalf of my fellow Directors for the outstanding contribution he has made.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
In the United States, ResAppDx is an investigational device and is not available for sale.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.